FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

2025-09-08 – Press Releases – www.prnewswire.com

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ — Echosens, the leader in non-invasive liver diagnostics, is announcing today…

Read the full article here.